Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chihong Zhou
Observed name:
C.-C. Zhou
Institutions:
University of California Davis Medical Center,
University of California, Davis
Observed institutions:
University of California Davis Medical Center,
UC Davis Health,
UC Davis Comprehensive Cancer Center,
University of California, Davis
ORCID:
0000-0003-3249-4095
Observed ORCID:
0000-0003-3249-4095
OpenAlex ID:
A5091155896
Simultaneous Quantitation of Cocaine and Its Major Metabolites in Human Hair by Gas Chromatography/Chemical Ionization Mass Spectrometry
1991
·
Martha R. Harkey
, Gary L. Henderson
, et al.
·
Journal of Analytical Toxicology
·
120
High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer
2020
·
Qianping Li
, Weijie Ma
, et al.
·
Translational Lung Cancer Research
·
33
PDF
MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway
2020
·
J.-H. Fu
, S. Yang
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
·
18
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
·
Molecular Cancer Therapeutics
·
12
PDF
Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer
2023
·
Weijie Ma
, Jie Zeng
, et al.
·
Cancers
·
7
PDF
Integrin α3 (ITGA3) expression across breast cancer subtypes: Prognosis and therapeutic relevance
2026
·
Weijie Ma
, Hongyuan Zhao
, et al.
·
Cancer Pathogenesis and Therapy
·
2
Four Cases of Esophageal Diverticulum Presented as Incidentally Discovered Asymptomatic Posterior Thyroid Nodules
2019
·
Guofeng Gao
, Chihong Zhou
·
American Journal of Clinical Pathology
·
1
Supplementary Table S3 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Table S2 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S6 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S3 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S1 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S4 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S5 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Table S1 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S2 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2026
·
Weijie Ma
, Sixi Wei
, et al.
Data from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S2 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Table S2 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Table S1 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Fig S4 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Table S3 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
Supplementary Fig S1 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Table S1 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Supplementary Fig S3 from Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
2024
·
Weijie Ma
, Sixi Wei
, et al.
PDF
Show more works
View as search
Works count:
35
Citation count:
193
H-index:
5
I10-index:
4
Year
Topic
Type